QIAGEN N.V. (QIA.DE) Stock Price, Forecast & Analysis
FRA:QIA • NL0015002SN0
QIA.DE Key Statistics, Chart & Performance
The current stock price of QIA.DE is 40.985 EUR. In the past month the price decreased by -11.15%. In the past year, price increased by 4.18%.
QIA.DE Technical Analysis
QIA.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to QIA.DE. QIA.DE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
QIA.DE Financial Highlights
Over the last trailing twelve months QIA.DE reported a non-GAAP Earnings per Share(EPS) of 2.1. The EPS increased by 10.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.33% | ||
| ROA | 6.75% | ||
| ROE | 11.25% | ||
| Debt/Equity | 0.44 |
QIA.DE Forecast & Estimates
24 analysts have analysed QIA.DE and the average price target is 46.2 EUR. This implies a price increase of 12.73% is expected in the next year compared to the current price of 40.985.
For the next year, analysts expect an EPS growth of 8.94% and a revenue growth 6.28% for QIA.DE
QIA.DE Ownership
QIA.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SRT3 | SARTORIUS AG-VORZUG | 39.5 | 17.896B | ||
| DIM | SARTORIUS STEDIM BIOTECH | 34.25 | 17.787B | ||
| 56S1 | SARTORIUS STEDIM BIOTECH | 33.94 | 17.626B | ||
| SRT | SARTORIUS AG | 32.59 | 14.766B | ||
| 1SXP | SCHOTT PHARMA AG& CO KGAA | 13.46 | 2.298B | ||
| EVT | EVOTEC SE | N/A | 2.168B | ||
| GXI | GERRESHEIMER AG | 6.81 | 705.998M | ||
| FF | FINE FOODS & PHARMACEUTICALS | 16.41 | 254.242M | ||
| ALECR | EUROFINS CEREP-REGR | N/A | 174M |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About QIA.DE
Company Profile
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Company Info
QIAGEN N.V.
Hulsterweg 82
Venlo LIMBURG NL
Employees: 5700
Phone: 31773556600
QIAGEN N.V. / QIA.DE FAQ
What does QIA do?
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Can you provide the latest stock price for QIAGEN N.V.?
The current stock price of QIA.DE is 40.985 EUR. The price decreased by -0.82% in the last trading session.
Does QIAGEN N.V. pay dividends?
QIAGEN N.V. (QIA.DE) has a dividend yield of 0.52%. The yearly dividend amount is currently 0.
What is the ChartMill technical and fundamental rating of QIA stock?
QIA.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is QIAGEN N.V. (QIA.DE) stock traded?
QIA.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is QIAGEN N.V. worth?
QIAGEN N.V. (QIA.DE) has a market capitalization of 8.44B EUR. This makes QIA.DE a Mid Cap stock.